News Archive

Oral anticoagulation (OAC), a treatment strategy commonly used to prevent stroke in patients with atrial fibrillation, may be harmful for patients with atrial fibrillation and end-stage renal disease, according to a recent study led by the DCRI. The study, which was led by the DCRI’s Sean Pokorney, MD, MBA, and published in Journal of the American College of Cardiology, used Medicare claims data to analyze a cohort of over 8,000 patients with both atrial fibrillation and end-stage renal disease.

A study led by DCRI and Duke researchers was the first to comprehensively explore skin tone as a potential factor affecting accuracy of heart rate measurements from wearable devices.

When compared to patients with non-advanced heart failure, patients with advanced heart failure had a more than three-fold higher risk of dying within a year after receiving a defibrillator.

The DCRI’s Manesh Patel, MD, who was a member of the steering committee for this late-breaking clinical trial, has been working for years to determine the best treatment strategies for patients with peripheral artery disease.

Recent evidence suggests that a novel oral anticoagulant plus a P2Y12 inhibitor may be the best treatment pathway for patients with atrial fibrillation undergoing percutaneous coronary intervention. DCRI faculty contributed to a meta-analysis recently published in JAMA Cardiology, which drew data from five clinical trials, including DCRI-led AUGUSTUS, to evaluate the safety and efficacy of four different antithrombotic regimens.

A paper recently published in JAMA Cardiology details the design of ADAPTABLE, a DCRI-led pragmatic clinical trial that uses many novel elements to efficiently answer a question that has substantial impacts on public health. ADAPTABLE seeks to determine the optimal dose of aspirin for patients with heart disease. Although aspirin has been used as a secondary prevention method for nearly three decades, the question of whether low-dose or high-dose aspirin is more beneficial remains unanswered.

The study sought to simultaneously test a method for identifying individuals at high risk for Alzheimer’s disease while testing the efficacy of a potential treatment aimed at targets affecting cell

A report from an NIH Health Care Systems Research Collaboratory roundtable recently published in 

Although initial results from SECURE-PCI suggested that patients treated with periprocedural loading doses of atorvastatin and undergoing percutaneous coronary intervention (PCI) experienced a reduced risk of major adverse cardiovascular events (MACE), extended follow-up showed no significant difference. The 12-month results, which were recently published in JAMA, expand upon the initial study, which followed patients for 30 days.

From thought leadership on a national stage to driving adoption for digital health technologies, the DCRI is leading the way in the digital therapeutic space.